Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient... Show more
The 10-day moving average for IOVA crossed bullishly above the 50-day moving average on January 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 50-day moving average for IOVA moved above the 200-day moving average on January 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for IOVA moved out of overbought territory on December 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on February 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IOVA as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on February 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
IOVA moved below its 50-day moving average on February 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IOVA broke above its upper Bollinger Band on January 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.374) is normal, around the industry mean (26.526). P/E Ratio (0.000) is within average values for comparable stocks, (51.406). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.895). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (3.219) is also within normal values, averaging (329.988).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a developer of biotechnological products for the treatment of cancer
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| HLRRX | 9.40 | 0.09 | +0.97% |
| LDR Real Estate Value Opportunity Instl | |||
| LMASX | 35.27 | 0.33 | +0.94% |
| ClearBridge Small Cap C | |||
| SSAIX | 15.42 | 0.07 | +0.46% |
| State Street International Stock Sel N | |||
| UINQX | 59.70 | -1.08 | -1.78% |
| Victory Nasdaq 100 Index Institutional | |||
| MTCCX | 37.40 | -1.09 | -2.83% |
| MFS Technology C | |||
A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with PLX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then PLX could also see price increases.
| Ticker / NAME | Correlation To IOVA | 1D Price Change % | ||
|---|---|---|---|---|
| IOVA | 100% | -7.58% | ||
| PLX - IOVA | 47% Loosely correlated | +6.23% | ||
| VCYT - IOVA | 43% Loosely correlated | -4.35% | ||
| CLDX - IOVA | 43% Loosely correlated | -3.58% | ||
| MGNX - IOVA | 42% Loosely correlated | -1.14% | ||
| IDYA - IOVA | 41% Loosely correlated | -2.78% | ||
More | ||||